Replies to post #615916 on NorthWest Biotherapeutics Inc (NWBO)
08/01/23 2:45 AM
If nwbo does submit in the UK, I expect it to be rejected. Results are marginal once adjusted for nwbo advantages over competitors in full resection, KPS score, patient health, etc. No patient level data. Way too many warts on a 15+ year trial that went from P2 to P3, upsize, unexplained FDA halt, unbalanced enrollment, etc.
08/01/23 7:05 AM
08/01/23 7:05 AM
08/01/23 7:16 AM
08/01/23 7:26 AM
08/01/23 7:34 AM
08/01/23 7:42 AM
08/01/23 7:46 AM
08/01/23 8:36 AM
08/01/23 8:37 AM
08/01/23 9:02 AM
08/01/23 9:07 AM
08/01/23 9:10 AM
08/01/23 9:10 AM
08/01/23 9:47 AM
08/01/23 10:10 AM
08/01/23 10:10 AM
08/01/23 10:41 AM
08/01/23 11:53 AM
08/01/23 12:34 PM
There might be one more pump if nwbo ever gets around to submitting in the UK. Have a plan. If that gets the stock over $1, stick to your plan and be smart rather than greedy.
If nwbo does submit in the UK, I expect it to be rejected. Results are marginal once adjusted for nwbo advantages over competitors in full resection, KPS score, patient health, etc. No patient level data. Way too many warts on a 15+ year trial that went from P2 to P3, upsize, unexplained FDA halt, unbalanced enrollment, etc.
LP might still try to keep the saga going with the story that some change in FDA regs make the US a better bet. That could also be the excuse if they don't submit in the UK.
04/17/24 5:53 PM
04/17/24 5:55 PM
I believe that your assumption that the UK and other regulators won't approve is wrong for two reasons. The first is that I believe that DCVax-L will be the first applicant to show it increases 5 year survival dramatically. Granted, other products in trial may be achieving comparable numbers, but not dramatically better. The second, and really most important one is that the regulators are not deaf, dumb, and blind, they know that DCVax-L is opening the door to treatment by a number of existing therapeutics that previously failed in GBM that suddenly take survival at 5 years to 50% or greater, roughly ten times what's achieved by the current SOC. To ignore such information and demand years of additional trials on their part would be malpractice by the regulators IMHO. Likewise, post approval it would be malpractice for a Dr. to use DCVax-L and not use one or more of the existing therapeutics documented to dramatically increase the efficacy of DCVax-L.
Gary
skitahoe 6105 - You seem like a nice guy, but please try to be less naive about believing things you WANT to be true.
| Volume | |
| Day Range: | |
| Bid Price | |
| Ask Price | |
| Last Trade Time: |